Biohaven licensing deal with Ono Pharma for extracellular IgG degraders in Japan
Biohaven (BHVN) signed a licensing agreement with Ono Pharma for extracellular IgG degraders in Japan and select Asian regions, with Biohaven to receive $80M upfront.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.